{"brief_title": "Effects of Exenatide and Insulin Glargine in Subjects With Type 2 Diabetes", "brief_summary": "This Phase 3, open-label, multicenter study is designed to compare the effects of exenatide and insulin glargine (Lantus\u00ae injection) on beta-cell function in patients with type 2 diabetes mellitus using metformin.", "condition": ["Type 2 Diabetes Mellitus"], "intervention_type": ["Drug", "Drug", "Drug"], "intervention_name": ["exenatide", "Insulin glargine", "Metformin"], "description": ["subcutaneous injection, titrated up to a maximum of 20mcg three times a day in order to meet defined blood glucose targets", "subcutaneous injection, once a day, titrated as necessary in order to meet defined blood glucose targets", "Patients usual dosage"], "arm_group_label": ["Exenatide Arm", "Insulin Glargine Arm", "Exenatide Arm", "Insulin Glargine Arm"], "other_name": ["Byetta", "Lantus"], "criteria": "Inclusion Criteria: - Diagnosis of type 2 diabetes, but otherwise healthy - HbA1c between 6.6% and 9.5%, inclusive. - Body mass index (BMI) of 25 kg/m2 to 40 kg/m2, inclusive. - Treated with a stable dose of metformin for at least 2 months prior to screening. Exclusion Criteria: - Patients previously in a study using exenatide. - Treated with oral anti-diabetic medications other than metformin within 2 months of screening (thiazolidinediones within 5 months of screening). - Treated with insulin within 3 months of screening.", "gender": "All", "minimum_age": "30 Years", "maximum_age": "75 Years", "healthy_volunteers": "No", "keyword": "Lilly", "mesh_term": ["Diabetes Mellitus", "Diabetes Mellitus, Type 2", "Insulin, Globin Zinc", "Exenatide", "Insulin", "Metformin", "Insulin Glargine"], "id": "NCT00097500"}